貝達藥業(300558.SZ)2020年度淨利潤預增155%至185%
格隆匯 1 月 28日丨貝達藥業(300558.SZ)公佈,預計2020年度歸屬於上市公司股東的淨利潤58859.51萬元至65784.16萬元,同比增長155%至185%。
報吿期內,公司營業收入繼續保持良好的增長態勢,預計歸屬於上市公司股東的淨利潤同比大幅上升。由於埃克替尼療效確切、肝毒性低、安全性高,循證醫學臨牀證據豐富,中國人羣數據全,在CSCO指南、衞健委診療規範及腦轉移人羣、21-L858R NSCLC 患者中獲優先推薦,也是目前唯一繼續開展後續免費用藥項目的一代EGFR-TKI 原研藥,具有明顯的差異化優勢。憑藉前述差異化優勢及多年的口碑積累,埃克替尼銷量繼續穩步增長。此外,報吿期內公司新藥ALK抑制劑恩沙替尼獲批上市並已產生銷售收入。
報吿期內,非經常性損益對淨利潤的影響金額預計為2.6億元至2.8億元,主要系公司出售浙江貝達醫藥科技有限公司股權的投資收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.